Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.
Prostate local relapse
Prostate reirradiation
Reirradiation
Stereotactic body radiotherapy
Volumetric modulated arc radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
02
09
2022
accepted:
04
01
2023
medline:
29
5
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
The rates of local failure after curative radiotherapy for prostate cancer (PC) remain high despite more accurate locoregional treatments available, with one third of patients experiencing biochemical failure and clinical relapse occurring in 30-47% of cases. Today, androgen deprivation therapy (ADT) is the treatment of choice in this setting, but with not negligible toxicity and low effects on local disease. Therefore, the treatment of intraprostatic PC recurrence represents a challenge for radiation oncologists. Prostate reirradiation (Re-I) might be a therapeutic possibility. We present our series of patients treated with salvage stereotactic Re‑I for intraprostatic recurrence of PC after radical radiotherapy, with the aim of evaluating feasibility and safety of linac-based prostate Re‑I. We retrospectively evaluated toxicities and outcomes of patients who underwent salvage reirradiation using volumetric modulated arc therapy (VMAT) for intraprostatic PC recurrence. Inclusion criteria were age ≥ 18 years, histologically proven diagnosis of PC, salvage Re‑I for intraprostatic recurrence after primary radiotherapy for PC with curative intent, concurrent/adjuvant ADT with stereotactic body radiation therapy (SBRT) allowed, performance status ECOG 0-2, restaging choline/PSMA-PET/TC and prostate MRI after biochemical recurrence, and signed informed consent. From January 2019 to April 2022, 20 patients were recruited. Median follow-up was 26.7 months (range 7-50). After SBRT, no patients were lost at follow-up and all are still alive. One- and 2‑year progression free survival (PFS) was 100% and 81.5%, respectively, while 2‑year biochemical progression-free survival (bFFS) was 88.9%. Four patients (20%) experienced locoregional lymph node progression and were treated with a further course of SBRT. Prostate reirradiation allowed the ADT start to be postponed for 12-39 months. Re‑I was well tolerated by all patients and none discontinued the treatment. No cases of ≥ G3 genitourinary (GU) or gastrointestinal (GI) toxicity were reported. Seven (35%) and 2 (10%) patients experienced acute G1 and G2 GU toxicity, respectively. Late GU toxicity was recorded in 10 (50%) patients, including 8 (40%) G1 and 2 (10%) G2. ADT-related side effects were found in 7 patients (hot flashes and asthenia). Linac-based SBRT is a safe technique for performing Re‑I for intraprostatic recurrence after primary curative radiotherapy for PC. Future prospective, randomized studies are desirable to better understand the effectiveness of reirradiation and the still open questions in this field.
Sections du résumé
BACKGROUND
The rates of local failure after curative radiotherapy for prostate cancer (PC) remain high despite more accurate locoregional treatments available, with one third of patients experiencing biochemical failure and clinical relapse occurring in 30-47% of cases. Today, androgen deprivation therapy (ADT) is the treatment of choice in this setting, but with not negligible toxicity and low effects on local disease. Therefore, the treatment of intraprostatic PC recurrence represents a challenge for radiation oncologists. Prostate reirradiation (Re-I) might be a therapeutic possibility. We present our series of patients treated with salvage stereotactic Re‑I for intraprostatic recurrence of PC after radical radiotherapy, with the aim of evaluating feasibility and safety of linac-based prostate Re‑I.
MATERIALS AND METHODS
We retrospectively evaluated toxicities and outcomes of patients who underwent salvage reirradiation using volumetric modulated arc therapy (VMAT) for intraprostatic PC recurrence. Inclusion criteria were age ≥ 18 years, histologically proven diagnosis of PC, salvage Re‑I for intraprostatic recurrence after primary radiotherapy for PC with curative intent, concurrent/adjuvant ADT with stereotactic body radiation therapy (SBRT) allowed, performance status ECOG 0-2, restaging choline/PSMA-PET/TC and prostate MRI after biochemical recurrence, and signed informed consent.
RESULTS
From January 2019 to April 2022, 20 patients were recruited. Median follow-up was 26.7 months (range 7-50). After SBRT, no patients were lost at follow-up and all are still alive. One- and 2‑year progression free survival (PFS) was 100% and 81.5%, respectively, while 2‑year biochemical progression-free survival (bFFS) was 88.9%. Four patients (20%) experienced locoregional lymph node progression and were treated with a further course of SBRT. Prostate reirradiation allowed the ADT start to be postponed for 12-39 months. Re‑I was well tolerated by all patients and none discontinued the treatment. No cases of ≥ G3 genitourinary (GU) or gastrointestinal (GI) toxicity were reported. Seven (35%) and 2 (10%) patients experienced acute G1 and G2 GU toxicity, respectively. Late GU toxicity was recorded in 10 (50%) patients, including 8 (40%) G1 and 2 (10%) G2. ADT-related side effects were found in 7 patients (hot flashes and asthenia).
CONCLUSION
Linac-based SBRT is a safe technique for performing Re‑I for intraprostatic recurrence after primary curative radiotherapy for PC. Future prospective, randomized studies are desirable to better understand the effectiveness of reirradiation and the still open questions in this field.
Identifiants
pubmed: 36732443
doi: 10.1007/s00066-023-02043-3
pii: 10.1007/s00066-023-02043-3
pmc: PMC10212806
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
554-564Informations de copyright
© 2023. The Author(s).
Références
Clin Oncol (R Coll Radiol). 2018 Feb;30(2):93-100
pubmed: 29208480
Technol Cancer Res Treat. 2017 Dec;16(6):1194-1201
pubmed: 29333958
World J Urol. 2021 Apr;39(4):1161-1170
pubmed: 32591899
Front Pharmacol. 2021 Nov 01;12:746853
pubmed: 34790123
Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):614-621
pubmed: 30825495
World J Clin Oncol. 2017 Aug 10;8(4):305-319
pubmed: 28848697
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818785496
pubmed: 29983098
Crit Rev Oncol Hematol. 2013 Dec;88(3):550-63
pubmed: 23953795
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):291-299
pubmed: 31629838
Technol Cancer Res Treat. 2012 Dec;11(6):591-7
pubmed: 22568625
Brachytherapy. 2015 May-Jun;14(3):342-9
pubmed: 25727178
World J Urol. 2016 Mar;34(3):311-7
pubmed: 26062525
Cancers (Basel). 2022 May 23;14(10):
pubmed: 35626168
Strahlenther Onkol. 2014 Feb;190(2):165-70
pubmed: 24317192
J Clin Oncol. 2009 Apr 1;27(10):1549-56
pubmed: 19237635
Cancer Treat Rev. 2021 Apr;95:102176
pubmed: 33743409
Rep Pract Oncol Radiother. 2022 Mar 22;27(1):1-9
pubmed: 35402024
Technol Cancer Res Treat. 2003 Aug;2(4):339-44
pubmed: 12892517
Curr Oncol. 2022 Apr 22;29(5):2995-3012
pubmed: 35621634
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Brachytherapy. 2014 Jan-Feb;13(1):53-8
pubmed: 24295965
Cancers (Basel). 2022 Jun 29;14(13):
pubmed: 35804958
J Urol. 2001 Apr;165(4):1146-51
pubmed: 11257657
Cancer. 2007 Oct 1;110(7):1405-16
pubmed: 17685384
Radiother Oncol. 2015 May;115(2):186-90
pubmed: 25935742
World J Urol. 2019 Dec;37(12):2631-2637
pubmed: 30859273
Pract Radiat Oncol. 2015 Nov-Dec;5(6):e615-23
pubmed: 26059509
Cancers (Basel). 2021 Aug 27;13(17):
pubmed: 34503149
Cancers (Basel). 2022 May 28;14(11):
pubmed: 35681659
Cancer Radiother. 2019 Oct;23(6-7):541-558
pubmed: 31421999
Curr Oncol. 2022 Mar 09;29(3):1866-1876
pubmed: 35323352
Nat Clin Pract Urol. 2009 Feb;6(2):76-85
pubmed: 19198621
Radiat Oncol. 2021 Jun 23;16(1):114
pubmed: 34162398
Cancer Radiother. 2016 Jun;20(4):275-81
pubmed: 27342944
BJU Int. 2012 Mar;109(6):835-9
pubmed: 21933327
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44
pubmed: 20138442
Cancer. 2007 Oct 1;110(7):1417-28
pubmed: 17694553
Radiother Oncol. 2016 Jun;119(3):405-10
pubmed: 27165612
Br J Radiol. 2017 Nov;90(1079):20170021
pubmed: 28830203
Radiother Oncol. 2014 Jul;112(1):77-82
pubmed: 24998704
Ann Palliat Med. 2022 Nov;11(11):3555-3561
pubmed: 35871277
Radiat Oncol. 2017 Jun 9;12(1):95
pubmed: 28599663
Expert Rev Anticancer Ther. 2020 Nov;20(11):947-956
pubmed: 32909471
J Contemp Brachytherapy. 2009 Jun;1(2):105-108
pubmed: 27795720
Brachytherapy. 2017 Nov - Dec;16(6):1091-1098
pubmed: 28838648
Front Oncol. 2021 Jan 08;10:603994
pubmed: 33585223
Brachytherapy. 2010 Apr-Jun;9(2):119-25
pubmed: 19850536
Br J Radiol. 2020 Dec 01;93(1116):20200951
pubmed: 33035077
Urol Int. 2013;90(3):294-300
pubmed: 23467122
Rep Pract Oncol Radiother. 2020 Mar-Apr;25(2):157-162
pubmed: 32021569
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9
pubmed: 23474112
J Contemp Brachytherapy. 2019 Apr;11(2):101-107
pubmed: 31139217
Br J Radiol. 2019 Feb;92(1094):20180494
pubmed: 30379566
Crit Rev Oncol Hematol. 2021 Nov;167:103500
pubmed: 34688894
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Neoplasma. 2021 Jan;68(1):216-226
pubmed: 33030959
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1106-12
pubmed: 17197119
Curr Oncol. 2022 Jun 30;29(7):4612-4624
pubmed: 35877226
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BJU Int. 2009 Sep;104(5):600-4
pubmed: 19245439
Strahlenther Onkol. 2022 Aug;198(8):700-709
pubmed: 34757443
J Urol. 2019 Oct;202(4):725-731
pubmed: 31075058
Front Oncol. 2022 Apr 13;12:858740
pubmed: 35494082
Strahlenther Onkol. 2020 Jul;196(7):628-636
pubmed: 32399638
Clin Oncol (R Coll Radiol). 2022 Jan;34(1):57-62
pubmed: 34598843
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
Radiother Oncol. 2016 Jan;118(1):122-30
pubmed: 26549865
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):318-322
pubmed: 27475672
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1172-1178
pubmed: 32659332
Front Oncol. 2021 Jul 14;11:690422
pubmed: 34336678
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1455-62
pubmed: 16169682
Prostate Cancer. 2016;2016:9561494
pubmed: 27092279
Front Oncol. 2019 Feb 15;9:71
pubmed: 30828565
Eur Urol Oncol. 2020 Apr;3(2):183-197
pubmed: 31411996
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7
pubmed: 22672747
Clin Med Insights Oncol. 2017 Nov 07;11:1179554917738765
pubmed: 29151782